IDORSIA LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.906 CHF | -4.70% |
|
+4.73% | -9.84% |
| Apr. 11 | Swiss Market Index Falls as ECB Signals June Rate Cut | MT |
| Apr. 11 | Idorsia to Revise July 2024 Convertible Bond Terms, Conditions | MT |
| Sales 2023 * | 126M 138M | Sales 2024 * | 272M 297M | Capitalization | 341M 373M |
|---|---|---|---|---|---|
| Net income 2023 * | -407M -445M | Net income 2024 * | -401M -438M | EV / Sales 2023 * | 11.3 x |
| Net Debt 2023 * | 1.08B 1.18B | Net Debt 2024 * | 1.12B 1.23B | EV / Sales 2024 * | 5.39 x |
| P/E ratio 2023 * |
-0.92
x | P/E ratio 2024 * |
-1.34
x | Employees | 650 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 58.73% |
More Fundamentals
* Assessed data
More news
Latest transcript on Idorsia Ltd
More recommendations
More press releases
| 1 day | -4.70% | ||
| 1 week | -11.35% | ||
| Current month | -32.60% | ||
| 1 month | -10.35% | ||
| 3 months | +38.62% | ||
| 6 months | +2.31% | ||
| Current year | -9.84% |
1 week
1.80
2.15
1 month
1.652.97
Current year
1.293.70
1 year
1.299.75
3 years
1.2927.08
5 years
1.2933.88
10 years
1.2933.88
| Managers | Title | Age | Since |
|---|---|---|---|
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 17-05-31 |
André Muller
DFI | Director of Finance/CFO | 60 | 17-05-31 |
Martine Clozel
CTO | Chief Tech/Sci/R&D Officer | 68 | 17-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jörn Aldag
BRD | Director/Board Member | 65 | 20-05-12 |
Peter Kellogg
BRD | Director/Board Member | 67 | 21-05-11 |
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 17-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 1.906 | -4.70% | 360,301 |
| 24-04-23 | 2 | 0.00% | 784,329 |
| 24-04-22 | 2 | +1.52% | 309,561 |
| 24-04-19 | 1.97 | +1.03% | 557,270 |
| 24-04-18 | 1.95 | +7.14% | 890,742 |
Delayed Quote Swiss Exchange, April 24, 2024 at 11:31 am EDT
More quotes
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Calendar
01:00am
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
1.906
CHF
Average target price
1.724
CHF
Spread / Average Target
-9.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.84% | 393M | |
| -1.51% | 105B | |
| +3.22% | 97.5B | |
| +1.86% | 22.19B | |
| -16.53% | 21.33B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -20.09% | 14.52B | |
| +5.47% | 14.09B | |
| +28.85% | 10.99B |
- Stock Market
- Equities
- IDIA Stock
